News

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research, networking opportunities, and empowering women in retina.

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

The country has a goal of ensuring that more than 95% of patients with diabetes receive timely retinal examinations.

Potential loss to follow-up is a critical issue for these patients with glaucoma.

Discover new insights into central serous chorioretinopathy, including pathophysiology, imaging techniques, and effective treatment options for better patient outcomes.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Guymer discusses early intervention strategies for intermediate AMD, highlighting risk factors, and potential trial designs to prevent vision loss.

IVMED-85 is a preservative-free prescription eye drop designed to prevent myopia progression in children.

We ask leading experts in the field what eye disease they would cure and why.

At the EURETINA congress, Prof Boon discussed controversies in treatment, some driven by critical prospective studies

By letting patients “see” their options before surgery, virtual reality may eliminate confusion, boost confidence, and strengthen surgeon–patient trust.

A new staging system for diabetic retinopathy and macular edema is essential, integrating advanced imaging techniques for better disease management and patient outcomes.

The future of diabetic retinal imaging will be impacted by the use of widefield OCT-A technology, enhancing diagnosis and monitoring while addressing current limitations.

The lesion area growth was reduced by more than 50% in the first human clinical trial of K8.

By combining anatomical fidelity with reproducibility, NRSS offers a novel way to train surgeons, validate clinical trials, and expand access to advanced techniques worldwide.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025

We ask leading experts in the field what eye disease they would cure and why.

Kalaris Therapeutics initiates a phase 1b/2 study for TH103, targeting neovascular age-related macular degeneration and advancing retinal disease treatment.

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

Mark your calendars: On September 26 and 27, 2025, the Ophthalmology Times and Optometry Times EyeCon 2025 conference will convene at the Margaritaville Hollywood Beach Resort in Hollywood, Florida.

K8 was found to reduce geographic atrophy lesion area growth by more than 50% in its first human clinical trial of the drug.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.